Patents Assigned to Concert Pharmaceuticals Inc.
  • Morphinan compounds
    Patent number: 9072711
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 7, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
    Patent number: 9074233
    Abstract: The present invention provides a process for the preparation of enantiomerically enriched, deuterated secondary alcohols of Formula 1-A by employing ketoreductases or carbonyl reductases without reducing deuterium incorporation.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: July 7, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Ramanaiah C. Kanamarlapudi, Steven A. Weissman, Emerich Eisenreich, Xuejun Liu
  • DEUTERATED CARFILZOMIB
    Publication number: 20150166601
    Abstract: The present invention in one embodiment provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification. The compound of Formula (I) is useful for the treatment of diseases such as a disease selected from the group consisting of multiple myeloma, solid tumors, lymphoma, and leukemia.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 18, 2015
    Applicant: CONCERT PHARMACEUTICALS INC.
    Inventors: Adam Morgan, Roger Tung
  • Deuterated Idebenone
    Publication number: 20150166449
    Abstract: The present invention in one embodiment provides a compound of Formula I:(I), or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 18, 2015
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • 4-hydroxybutyric acid analogs
    Patent number: 9051261
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: June 9, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Substituted dioxopiperidinyl phthalimide derivatives
    Patent number: 9045453
    Abstract: This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 2, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • PYRAZINOISOQUINOLINE COMPOUNDS
    Publication number: 20150141431
    Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Application
    Filed: October 20, 2014
    Publication date: May 21, 2015
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
  • Substituted xanthine derivatives
    Patent number: 9035050
    Abstract: This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R1, R2, R3, R4, R5, Y1 and Y2 are described herein.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: May 19, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES
    Publication number: 20150105438
    Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
    Type: Application
    Filed: September 19, 2014
    Publication date: April 16, 2015
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventor: Julie F. Liu
  • Substituted triazolo-pyridazine derivatives
    Patent number: 8993570
    Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 31, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Roger Tung, Julie F. Liu
  • Deuterium-substituted xanthine derivatives and methods of use
    Patent number: 8987442
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: March 24, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • MORPHINAN COMPOUNDS
    Publication number: 20150073009
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Substituted xanthine derivatives
    Patent number: 8952016
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. The compound of the invention are represented by one of the following structural formulas: The variables for these structural formulas are described herein. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: February 10, 2015
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Inhibitors of Cholesterol Ester Transfer Protein
    Publication number: 20150011595
    Abstract: The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors.
    Type: Application
    Filed: May 6, 2014
    Publication date: January 8, 2015
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Substituted triazolo-pyridazine derivatives
    Patent number: 8921366
    Abstract: This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABA-A receptor antagonist and/or a ?2, ?3 and ?5 GABA-A receptor agonist.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: December 30, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Morphinan compounds
    Patent number: 8916582
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 23, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20140343119
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: April 17, 2014
    Publication date: November 20, 2014
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • Deuterated pyrazinoisoquinoline compounds
    Patent number: 8889687
    Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: November 18, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Roger Tung, Scott L. Harbeson
  • SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF
    Publication number: 20140336387
    Abstract: The present invention provides a convenient and efficient process for the synthesis of d2-benzo[d][1,3]dioxoles.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Andrew D. Jones, Robert E. Zelle, I. Robert Silverman
  • Substituted isoindoline-1,3-dione derivatives
    Patent number: 8883843
    Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogs of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: November 11, 2014
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Julie F. Liu